{"url":"https://newsforagent.com/news/2026-10-23/inocras-m42-mrdvision-uae-launch","markdown_url":"https://newsforagent.com/news/2026-10-23/inocras-m42-mrdvision-uae-launch.md","title":"Inocras and M42 Launch MRDVision Blood Test in UAE","headline":"Inocras and M42 Partner to Bring MRDVision Cancer Blood Test to the UAE","description":"Inocras and M42 will pilot the MRDVision blood test for high-risk breast cancer patients at Cleveland Clinic Abu Dhabi.","section":"Partnerships","published_at":"2026-10-23T05:25:29+00:00","modified_at":"2026-10-23T05:25:29+00:00","author":"News Desk","key_takeaways":["Inocras and M42 announced a partnership to bring the MRDVision minimal residual disease blood test to the United Arab Emirates.","The pilot will target high-risk breast cancer patients, including triple-negative and HER2-positive subtypes, at Cleveland Clinic Abu Dhabi.","M42 plans to assess performing the MRD test directly in its own UAE laboratories after the initial pilot."],"companies":[{"name":"Inocras","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000a8y/inocras","website":"https://inocras.com"},{"name":"M42","is_primary":false,"profile_url":"https://akta.pro/company-profiles/000mkso/m42","website":"https://m42.ae"}],"source":{"publisher":"Startup Researcher","title":"Inocras and M42 Partner to Launch MRDVision Blood Test in UAE","url":"https://www.startupresearcher.com/news/inocras-and-m42-partner-to-launch-mrdvision-blood-test-in-uae"},"other_sources":[],"tags":["Partnerships","Inocras","M42"],"body_markdown":"Inocras and M42 announced a partnership to bring MRDVision, a minimal residual disease blood test, to the United Arab Emirates, with a pilot at Cleveland Clinic Abu Dhabi for high-risk breast cancer patients. [Startup Researcher](https://www.startupresearcher.com/news/inocras-and-m42-partner-to-launch-mrdvision-blood-test-in-uae) reported the agreement was announced during the Abu Dhabi Future Health Summit, held October 20 to 22 at the Abu Dhabi National Exhibition Centre.\n\n## How the MRDVision Pilot Will Work\n\n[Inocras](https://akta.pro/company-profiles/0000a8y/inocras), a bioinformatics company focused on whole genome analysis, provides whole genome data and automated analysis through oncology and rare disease platforms from a CLIA/CAP certified laboratory. [M42](https://akta.pro/company-profiles/000mkso/m42) operates more than 480 facilities across 26 countries and integrates artificial intelligence, technology, and genomics into healthcare delivery.\n\nMRDVision begins with whole genome sequencing of a patient's tumor tissue to identify cancer-specific genetic alterations, then traces extremely small amounts of tumor DNA remaining in the bloodstream after treatment. The test targets thousands to tens of thousands of variants without requiring custom panels, and can detect tumor DNA at single-digit parts per million levels.\n\nThe pilot will include patients with triple-negative breast cancer and HER2-positive breast cancer, two subtypes known for aggressive behavior, and will gather real-world performance data from the UAE clinical environment. After the initial pilot, M42 plans to assess performing the MRD test directly in its own UAE laboratories.\n\nDavid Kavanagh, Head of Omics at M42, said the organization is building a genomic cancer care pathway that spans genetic risk identification, treatment decisions, and post-treatment management. Stephen Grobmyer, Chief of the Cancer Center at Cleveland Clinic Abu Dhabi, noted that tumor-informed blood tests can capture molecular signals before imaging confirms recurrence. Inocras CEO Jehee Suh added that the standardized test process will help generate local evidence quickly and could allow UAE patients to benefit sooner.\n\nM42 was formed in 2023 through the integration of G42 Healthcare and Mubadala Health, and its network includes Cleveland Clinic Abu Dhabi, Danat Al Emirat, and the Abu Dhabi Biobank. Cleveland Clinic Abu Dhabi is a multidisciplinary hospital with 406 beds and is designated as a Center of Excellence for breast cancer by the Department of Health Abu Dhabi.\n\n## Inocras Platforms Reach Hospitals and Biopharma\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Inocras' CancerVision and MRDVision platforms are deployed in over 20 hospitals with 100 oncologists and support more than 50 research and biopharma institutions worldwide. The company's genomic datasets include more than 10,000 whole genome data across various patient cohorts used for research services.\n\n## Inocras Funding and Partnerships Before the UAE Pilot\n\nIn August 2026, Inocras closed a $31 million Series B-3 round to expand in the U.S., targeting 10+ academic medical centers, and seeks Medicare reimbursement for its CancerVision platform by 2026-2027, with MRDVision following, the San Diego Business Journal reported. In July 2026, Inocras and AimedBio announced a strategic partnership to enhance cancer drug development using whole genome intelligence, with AimedBio investing in Inocras and integrating its WGS capabilities into its antibody-drug conjugate clinical programmes, Pharmaceutical Technology reported.\n\n## M42's Summit Announcements\n\nAt the Abu Dhabi Future Health Summit, M42 signed an agreement with Siemens Healthineers to collaborate on healthcare transformation in Africa, using digital health, AI, and imaging for prevention and screening, African Business reported. M42 also announced plans to develop Mubadala Health Bahrain, a new multidisciplinary healthcare facility offering services across 20 specialties, including six surgical inpatient specialties, and employing about 200 people, EIN Presswire reported.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}